Omnix Medical’s pipeline maintains three major programs based on unique antimicrobial peptides in various stages of development.
The Company’s lead compound OMN6 targeting Gram-negative bacteria is currently in IND-enabling studies and is expected to enter clinical Phase I trials in 2021. OMN6 has been found safe, stable and highly effective on multidrug-resistant Acinetobacter baumannii (AB), especially Carbapenem-resistant AB (CRAB), the #1 priority pathogen according to the WHO/CDC. This compound is being developed as systemic IV treatment for patients suffering from severe or life-threatening infections. OMN6 has been designated Qualified Infectious Disease Product (QIDP) by the FDA for the following indications:
- Hospital/Ventilator Associated Bacterial Pneumoniae (HABP/VABP)
- Blood Stream Infections (BSI)
- Complicated Urinary Tract Infections (cUTI)
OMN-Xf is a family of novel peptides in discovery stage at Omnix lab. OMNXf are being screened and developed as a therapy to treat infections caused by multidrug-resistant pathogenic Fungi. Where the arsenal of available therapies is limited.
OMN-GP is developed to treat infections caused by multidrug-resistant pathogenic Gram-positive bacteria, targeting pathogens like Methicillin-resistant Staphylococcus aureus (MRSA).